Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7549 USD -3.22% Market Closed
Market Cap: 26.7m USD

Equillium Inc
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Equillium Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Equillium Inc
NASDAQ:EQ
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Interest Paid
$2.8B
CAGR 3-Years
1%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Cash Interest Paid
$951m
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Cash Interest Paid
$3.3B
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Interest Paid
$30.5m
CAGR 3-Years
-18%
CAGR 5-Years
-11%
CAGR 10-Years
-8%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Interest Paid
$52.6m
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
10%

Equillium Inc
Glance View

Market Cap
26.7m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
0.847 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

Back to Top